Carmell Awarded U.S. Patent for Plasma-based Materials in Drug Delivery
Carmell Therapeutics received U.S. Patent No. 9,364,503, broadly covering the use of plasma-based materials (PBMs) as vehicles for delivering antimicrobials, analgesics, anti-inflammatory drugs and other drugs and proteins. This new patent brings Carmell’s total portfolio to 8 U.S. and 9 foreign issued patents. Additional U.S. and foreign patents remain pending.
PBMs are manufactured from pooled human blood plasma that is treated to inactivate viruses, then freeze dried into powder and plasticized to create pastes, putties, scaffolds, plugs and screws. Carmell's first product in development is REPAIR™ Putty to augment bone fractures. The new patent focuses on novel PBMs that can deliver antimicrobials locally.
Studies have shown that use of REPAIR plasma-based bone putty reduced infections, sped bone healing and promoted rapid wound closure in the treatment of open tibia fractures.
Sources: Carmell Therapeutics, ORTHOWORLD Inc.